Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study

References

• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70:205.e1-16.
   Web of Science ®Google Scholar
• Scarisbrick JJ. New drugs in cutaneous T-cell lymphomas. Curr Opin Oncol. 2016;28:384–389.
   PubMed Web of Science ®Google Scholar
• Marquard L, Gjerdrum LM, Christensen IJ, et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53:267–277.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49:386–394.
   PubMed Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168:811–819.
   PubMed Web of Science ®Google Scholar
• van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23:3886–3896.
   PubMed Web of Science ®Google Scholar
• Dueñas-Gonzalez A, Coronel J, Cetina L, et al. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014;10:1433–1444.
   PubMed Web of Science ®Google Scholar
• Zambrano P, Segura-Pacheco B, Perez-Cardenas E, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005;5:44.
   PubMed Web of Science ®Google Scholar
• Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005;4:22.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18:1529–1538.
   PubMed Web of Science ®Google Scholar
• Mora-García MDL, Duenas-González A, Hernández-Montes J, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med. 2006;4:55.
   PubMed Web of Science ®Google Scholar
• Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol. 2011;39:1491–1499.
   PubMed Web of Science ®Google Scholar
• Arce C, Pérez-Plasencia C, González-Fierro A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006;1:e98.
   PubMed Web of Science ®Google Scholar
• De la Cruz-Hernández E, Perez-Plasencia C, Pérez-Cardenas E, et al. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep. 2011;25:399–407.
   PubMed Web of Science ®Google Scholar
• Dueñas-Gonzalez A, Vega MT, Martinez-Baños D, et al. Response to hydralazine-valproate in a patient with mycosis fungoides. Case Rep Med. 2010;2010:657579.
   PubMedGoogle Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials.Control. Clin Trials. 1989;10:1–10.
   Web of Science ®Google Scholar
• Jung SH, Lee T, Kim K, et al. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004;23:561–569.
   PubMed Web of Science ®Google Scholar
• Livak KJ. Allelic discrimination using fluorogenic probes and the 5ʹ nuclease assay. Genet Anal. 1999;14:143–149.
   PubMedGoogle Scholar
• Taja-Chayeb L, González-Fierro A, Miguez-Muñoz C, et al. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test. Pharmacogenet Genomics. 2011;21:894–901.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). J Clin Oncol. 2011;29:2598–2607.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Herrera A, Labardini J, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol. 2011;90:379–387.
   PubMed Web of Science ®Google Scholar
• Bauman J, Shaheen M, Verschraegen CF, et al. A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers. Transl Oncol. 2014;7:349–354.
   PubMed Web of Science ®Google Scholar
• Garcés-Eisele SJ, Cedillo-Carvallo B, Reyes-Núñez V, et al. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. J Clin Pharm Ther. 2014;39:368–375.
   PubMed Web of Science ®Google Scholar
• van Doorn R, Slieker RC, Boonk SE, et al. Epigenomic analysis of sézary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers. J Invest Dermatol. 2016;136:1876–1884.
   PubMed Web of Science ®Google Scholar
• Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2011;147:443–449.
   PubMedGoogle Scholar
• Haider A, Steininger A, Ullmann R, et al. Inactivation of RUNX3/p46 promotes cutaneous T-cell lymphoma. J Invest Dermatol. 2016;136:2287–2296.
   PubMed Web of Science ®Google Scholar
• Ferrara G, Pancione M, Votino C, et al. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. Br J Dermatol. 2014;170:1266–1275.
   PubMed Web of Science ®Google Scholar
• Rozati S, Cheng PF, Widmer DS, et al. Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL. Clin Cancer Res. 2016;22:2020–2031.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Reme T, Leonard W, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013;109:676–685.
   PubMed Web of Science ®Google Scholar
• Rempel E, Hoelting L, Waldmann T, et al. A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015;89:1599–1618.
   PubMed Web of Science ®Google Scholar
• Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. 2006;6:2.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107.
   PubMed Web of Science ®Google Scholar
• Walton TJ, Li G, Seth R, et al. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate. 2008;68:210–222.
   PubMed Web of Science ®Google Scholar
• Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025–7029.
   PubMed Web of Science ®Google Scholar
• Shaker S, Bernstein M, Momparler LF, et al. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2ʹ-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003;27:437–444.
   PubMed Web of Science ®Google Scholar
• Zhu WG, Lakshmanan RR, Beal MD, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001;61:1327–1333.
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, et al. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. Leuk Res. 2011;35:932–939.
   PubMed Web of Science ®Google Scholar
• Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2ʹ-deoxycytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int. 2008;8:16.
   PubMed Web of Science ®Google Scholar